GuideNephrology
International IgA Nephropathy Prediction Tool (adults and children, at and after biopsy)
Reading sheet on the Barbour et al. models estimating the risk of major GFR loss or kidney failure in IgA nephropathy.
Updated 3 November 2026
When to use it
Patients with biopsy-proven IgA nephropathy with Oxford (MEST-C) classification, to inform prognosis and stratify risk at biopsy or 1–2 years later. It is the preferred prediction method in the KDIGO guidelines.
What it is
Set of Cox survival models derived from international multi-ethnic cohorts (Europe, North America, China and Japan):
• Adults at biopsy (2019): 3,927 patients; outcome 50% eGFR decline or kidney failure.
• Adults 1–2 years after biopsy (2022): 2,507 derivation and 722 validation patients.
• Children at biopsy (2021): 1,060 children; outcome 30% eGFR decline or kidney failure.
• Children 1–2 years after biopsy (2024): 947 children.
Each has a version with and without race/ethnicity.
Keep reading in the app
- Variables
- Performance
- Use according to KDIGO 2025
- Limitations
Practical tip
Use the version that matches the timing: the at-biopsy model underestimates risk if applied later; an updated model exists for 1–2 years after biopsy.
2 more practical tips in the app.
Reference
- Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942-952.
- Barbour SJ, Coppo R, Er L, et al. Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int. 2021;99(6):1439-1450.
- Barbour SJ, Coppo R, Zhang H, et al. Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int. 2022;102(1):160-172.
- Barbour SJ, Coppo R, Er L, et al. Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy. Kidney Int. 2024;106(5):913-927.
- Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1-S71.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
